Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study
1996

Enhancement of Photodynamic Therapy by Mitomycin C

Sample size: 4 publication Evidence: moderate

Author Information

Author(s): P Baas, IPJ van Geel, H Oppelaar, M Meyer, JH Beynen, N van Zandwijk, FA Stewart

Primary Institution: The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital

Hypothesis

Can the combination of photodynamic therapy and mitomycin C improve treatment outcomes for patients with recurrent skin metastasis of mammary carcinoma?

Conclusion

The combination of photodynamic therapy and mitomycin C enhances treatment effectiveness while allowing for lower doses of both the photosensitizer and light.

Supporting Evidence

  • The combination of photodynamic therapy and mitomycin C allowed for a reduction in light dose while maintaining treatment effectiveness.
  • Skin photosensitivity was significantly reduced with lower doses of Photofrin compared to standard doses.
  • Three out of four patients showed progression of disease despite treatment, indicating the need for earlier intervention.

Takeaway

Doctors combined a special light treatment with a medicine to help treat skin cancer, and it worked better than using just the light alone.

Methodology

The study involved preclinical experiments on mice and a clinical pilot study on four patients, evaluating tumor response and skin photosensitivity.

Potential Biases

Potential bias due to the small number of patients and lack of a control group.

Limitations

The study had a small sample size and included patients with prior treatments, which may have affected healing and outcomes.

Participant Demographics

Four patients with recurrent mammary carcinoma skin metastases, ages 45 to 74.

Statistical Information

P-Value

<0.0001

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication